Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September

Rhea-AI Summary

Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotech company focused on developing advanced antibody complement therapeutics for severe autoimmune diseases, has announced its participation in three major healthcare investor conferences in September 2024. CEO Marino Garcia will present corporate overviews at:

1. Baird 2024 Global Healthcare Conference on September 11 at 2:00 p.m. ET in New York City
2. Cantor 2024 Global Healthcare Conference on September 17 at 10:55 a.m. ET in New York City
3. Stifel 2024 Virtual Immunology and Inflammation Summit on September 18 at 10:30 a.m. ET via Zoom

Live webcasts of the Cantor and Stifel conference presentations will be available on the company's website under the Investors section.

News Market Reaction – DNTH

+0.72%

1 alert

+0.72% News Effect

On the day this news was published, DNTH gained 0.72%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK and WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of September:

• Baird 2024 Global Healthcare Conference on September 11 at 2:00 p.m. ET in New York City
• Cantor 2024 Global Healthcare Conference on September 17 at 10:55 a.m. ET in New York City
• Stifel 2024 Virtual Immunology and Inflammation Summit on September 18 at 10:30 a.m. ET via Zoom
  

Live webcasts of the Company’s presentations at the Cantor and Stifel conferences may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

What investor conferences will Dianthus Therapeutics (DNTH) attend in September 2024?

Dianthus Therapeutics will participate in three healthcare investor conferences in September 2024: Baird Global Healthcare Conference on September 11, Cantor Global Healthcare Conference on September 17, and Stifel Virtual Immunology and Inflammation Summit on September 18.

Who will be presenting at the investor conferences for Dianthus Therapeutics (DNTH)?

Marino Garcia, the Chief Executive Officer of Dianthus Therapeutics, will be presenting corporate overviews at the three healthcare investor conferences in September 2024.

Will there be webcasts available for Dianthus Therapeutics' (DNTH) conference presentations?

Yes, live webcasts of Dianthus Therapeutics' presentations at the Cantor and Stifel conferences will be accessible under the 'News and Events' section in the Investors area of the company's website.

What is the focus of Dianthus Therapeutics' (DNTH) research and development?

Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases.